About Horizon Discovery
Horizon Discovery is a Healthcare company based in Cambridge (United Kingdom) founded in 2007 by Alberto Bardelli, and was acquired by PerkinElmer in November 2020. It operates as a genetically modified cell lines are developed using AAV gene-editing platform. Horizon Discovery has raised $46.29 million across 8 funding rounds from investors including PerkinElmer, Calculus Capital and University of Cambridge. Horizon Discovery has completed 2 acquisitions, including Dharmacon and Sage Research Labs. Its chief executive is Terry Pizzie. Its website horizondiscovery.com draws about 63 thousand monthly visits. Horizon Discovery offers products and services including Pin-pointâ„¢ Base Editing Reagents, CRISPR Guide RNA, siRNA, Custom Oligonucleotides, and Engineered Cell Lines. Its focus areas include Life Sciences, Genomics, Diversified and Life Sciences Platforms and Tools. Its legal entity is HORIZON DISCOVERY GROUP LIMITED. Its competitors include Quanterix, Arrakis Therapeutics, NanoString, Souzhou Ribo Life Science and LGC and 4 more; 4 of its 9 listed competitors have raised funding.
Company details
Developer of cell lines with genetic modification using AAV gene-editing platform. The company has cell line engineering, knockout cell lines, and reporter cell lines. It also provides services in T cell activation assay, lymphocyte reaction assay, T cell-mediated tumor cell lysis assay, ADCC, and CDC assays, gene-editing for immuno-oncology, CRISPR Screening, drug combination screening, in vitro assay, and in-vivo assay.
- Headquarters Cambridge, United Kingdom
- Founders Alberto Bardelli
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website horizondiscovery.com
- Social LinkedIn X Facebook YouTube
- Acquired by PerkinElmer (Nov 2020)
- Legal Name Horizon Discovery Group Limited
- Date of Incorporation 04 Mar, 2014
- Jurisdiction CAMBRIDGE, ENGLAND
- Total Equity Funding$46.29M (USD)
in 8 rounds
- InvestorsPerkinElmer
& 14 more
- Investments & AcquisitionsDharmacon
& 1 more
- Acquired byPerkinElmer
(Nov 2020)
Products & Services of Horizon Discovery
Horizon Discovery offers a comprehensive portfolio of products and services, including Pin-point™ Base Editing Reagents, CRISPR Guide RNA, siRNA, Custom Oligonucleotides, and Engineered Cell Lines.
Reagents for next-generation gene editing applications
Guides for CRISPR-Cas9 experiments in research
Small interfering RNA for RNA interference studies
Tailored DNA and RNA for specific research needs
Pre-engineered cells for functional genomics testing
Apps and channels of Horizon Discovery
its YouTube channel Horizon Discovery has 1.72K subscribers and 30 videos.
Videos from Horizon Discovery
The most watched videos on Horizon Discovery's YouTube channel, Horizon Discovery (1.72K subscribers). Click a video to play it here.
More on Horizon Discovery.
Funding Insights of Horizon Discovery
Horizon Discovery has successfully raised a total of $46.29M across 8 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $46.29M
- Total Rounds 8
- First Round $298,000
(Apr 2008)
- Investors Count 14
All 8 funding rounds of Horizon Discovery with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2018 | – | Post-IPO | – | – | |
| Aug 2017 | $105.77M | Post-IPO | – | – | – |
| Jun 2013 | $10.5M | Series C | – | Jonathan Milner | |
| May 2013 | – | Series C | – | – | |
| Sep 2011 | $18.6M | Series C | – | MVM | |
| Sep 2011 | $7M | Series C | – | – | – |
| Sep 2010 | $9.9M | Series B | – | DFJ | |
| Apr 2008 | $298,000 | Seed | – | – |
15 investors in total: 11 institutional and 4 angel.
Investors in Horizon Discovery
Horizon Discovery has secured backing from 15 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include PerkinElmer, Calculus Capital and University of Cambridge.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investment firm based out of USA | – | valueact.com | San Francisco, United States | |
Venture capital firm investing in seed & early-stage startups | – | wrencapital.co.uk | London, United Kingdom | |
Stage agnostic VC firm investing globally | 2004 | draperesprit.com | London, United Kingdom | |
UK venture capital investments are managed by Calculus Capital. | 1999 | calculuscapital.com | London, United Kingdom | |
Private equity investments in healthcare companies are managed. | 1997 | mvm.com | London, United Kingdom | |
Corporate-backed venture capital firm focused on the healthcare sector | – | roche.com/venturefund.htm | - | |
Tech companies are invested in by Parkwalk venture capital firm. | – | parkwalkadvisors.com | London, United Kingdom | |
US focused VC firm | – | dfj.com | Menlo Park, United States | |
Multiple courses and degrees are offered across diversified academic streams. | 1209 | cam.ac.uk | Cambridge, United Kingdom | |
- | – | bamburghcapital.com | - |
Investor details for Horizon Discovery
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Horizon Discovery
54 people are tracked at Horizon Discovery (7 in leadership, 5 in board & advisors, 42 in team).
| Name | Role | Group |
|---|---|---|
Alberto Bardelli | Co-Founder | Leadership |
Terry Pizzie | CEO | Leadership |
Matthew Russell | Global Head Of Information Technology | Leadership |
Jayesh Pankhania | CFO | Leadership |
Anna Copping | Group Head Of Tax | Leadership |
Kim Nichols | Head of Global Operations | Leadership |
Sebastien Allouis | Head Of Scientific Support | Leadership |
Susan Galbraith | Non-Executive Director | Board & advisors |
Vishal Gulati | Non-Executive Director | Board & advisors |
Susan Searle | Non-Executive Director | Board & advisors |
Margarita Krivitski | Non-Executive Director | Board & advisors |
Siddartha Kadia | Director | Board & advisors |
Ashley Wilson | Scientist I | Team |
Gary Morton | Data Analytics Manager | Team |
Daniel Barrett | Senior Azure Data Engineer | Team |
Lorenzo Pini | Senior Software Engineer | Team |
Ana Rebocho | Manager Bioproduction | Team |
Brito Gnanapragasam | Manager - Cell Line Engineering | Team |
Joe Harker | ERP Solutions Manager | Team |
Anastasia Skvortsova | Paralegal - Commercial Contracts Specialist | Team |
34 more people are available in the full profile.
Complete people profiles for Horizon Discovery
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Horizon Discovery
Horizon Discovery has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Dharmacon and Sage Research Labs.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
RNA oligonucleotide synthesis technology is provided for research applications. | dharmacon.com | Lafayette, United States | 1995 | Jul 2017 | $85M | |
Animal research models are developed and provided for scientific use. | sageresearchlabs.com | Saint Louis, United States | 2009 | Sep 2014 | $48M |
Complete acquisition details for Horizon Discovery
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Horizon Discovery
7 dated milestones of Horizon Discovery across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Horizon Discovery is founded.
- Funding First funding round of $298K.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Sage Research Labs.
- Acquisition Acquires Dharmacon.
- Funding Latest funding round, Post-IPO,.
- Exit Acquired by PerkinElmer.
Competitors of Horizon Discovery
Horizon Discovery has 9 listed competitors in our database, 4 of them funded. They include Quanterix, Arrakis Therapeutics, NanoString, Souzhou Ribo Life Science and LGC, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| quanterix.com | 2007 | Cambridge, United States | $99.5M | 141 | Assay kits for ultra-sensitive biomarker detection are developed. | |
| arrakistx.com | 2015 | Waltham, United States | $113M | 91 | Provider of tools for the analysis of RNA structures | |
| nanostring.com | 2003 | Seattle, United States | $107.93M | 652 | Tools for translational research and molecular diagnosis are developed. | |
| ribolia.com | 2007 | Suzhou, China | $200.79M | – | Nucleic acid drugs are developed via RNA interference technology. | |
| lgcgroup.com | 1842 | Teddington, United Kingdom | – | 901 | Molecular biology reagents and services are supplied to biotech industries. | |
| sourcebioscience.com | 1903 | Nottingham, United Kingdom | – | 273 | Multiple genomic services are provided for analysis and diagnostics. | |
| gpc-biotech.com | 1997 | Planegg, Germany | – | – | Oncology therapies for prostate cancer and lymphoma are developed. | |
| bioneer.com | 1992 | Daejeon, South Korea | – | 3 | Molecular biology products, technologies, and RNAi therapeutics are provided. | |
| beckman.com | 1935 | Brea, United States | – | – | Provider of products for biomedical testing for R&D, diagnostic and commercial applications |
Detailed competitors of Horizon Discovery
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Horizon Discovery
The website of Horizon Discovery (horizondiscovery.com) receives about 63.5K visits a month.
- Monthly visits63.5K
▼ 13.5% vs previous month
Websites whose visitors overlap most with Horizon Discovery. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| bioline.com | 100% | 42.9K | #824,098 | View details | |
| bpsbioscience.com | 100% | – | #779,448 | View details | |
| biosearchtech.com | 100% | 52K | #598,672 | View details | |
| novateinbio.com | 100% | – | #2,211,246 | View details | |
| cytoskeleton.com | 100% | 25.6K | #1,134,849 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Horizon Discovery
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as Horizon Discovery (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Horizon Discovery
Complete news archive for Horizon Discovery
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Horizon Discovery
Horizon Discovery was founded in 2007 and raised its 1st funding round 1 year after it was founded.
Horizon Discovery is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Terry Pizzie is the current CEO of Horizon Discovery.
Horizon Discovery is a funded company, having raised a total of $46.29M across 8 funding rounds to date. The company's 1st funding round was a Seed of $298K, raised on Apr 2008.
Developer of cell lines with genetic modification using AAV gene-editing platform. The company has cell line engineering, knockout cell lines, and reporter cell lines. It also provides services in T cell activation assay, lymphocyte reaction assay, T cell-mediated tumor cell lysis assay, ADCC, and CDC assays, gene-editing for immuno-oncology, CRISPR Screening, drug combination screening, in vitro assay, and in-vivo assay.
Horizon Discovery's top competitors include NanoString, Quanterix and Arrakis Therapeutics.
Horizon Discovery offers Pin-pointâ„¢ Base Editing Reagents, CRISPR Guide RNA, siRNA, Custom Oligonucleotides, and Engineered Cell Lines.
Horizon Discovery has made 2 acquisitions, including Dharmacon, and Sage Research Labs.
Horizon Discovery has 15 investors. Key investors include PerkinElmer, Calculus Capital, University of Cambridge, MVM Partners, and Draper Esprit.
Horizon Discovery operates through Horizon Discovery Group Limited.
Yes. Horizon Discovery was acquired by PerkinElmer in November 2020.